Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Clinical trial NCT04479306 · COMPLETED

Trial details

NCT number: NCT04479306
Sponsor: M.D. Anderson Cancer Center
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Lung Non-Small Cell Carcinoma Stage IIIB Lung Cancer AJCC v8 Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8

Start date: 2020-06-18
Primary completion: 2023-07-27
Enrollment: 37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.